← Library
Ipamorelin
Research Use
Also known as NNC 26-0161
Function
Primary
GH secretagogue · Sleep optimization
Secondary
Body composition · Anti-aging
Mechanism
Selective ghrelin / GHS-R1a agonist — stimulates pituitary GH release without significantly raising cortisol or prolactin; clean pulse profile.
Evidence
Pre-clinical / Observational
Research
Phase I/II (discontinued); robust animal data
Dosing
Range
100–300 mcg/dose
Frequency
1–3× daily; ideally fasted or pre-sleep
Route
Subcutaneous
Cycling
8–12 weeks on / 4 weeks off.
Benefits
- ·Selective GH release with minimal cortisol/prolactin rise
- ·Improved sleep depth
- ·Pairs synergistically with Mod GRF 1-29
Risks
- ·Mild hunger
- ·Possible IGF-1 elevation
- ·Theoretical neoplasia risk
Contraindications
- ·Active malignancy
- ·Pregnancy
Regulatory
Not FDA-approved; compounded/research use
Functional Groups
Cited Works
- Raun K et al. Ipamorelin, the first selective growth hormone secretagogue. Eur J Endocrinol. 1998;139:552.source